Literature DB >> 12764530

Extension of organ transplantation: some ethical considerations.

George J Agich1.   

Abstract

The concept of vital organ transplantation is critically analyzed by considering how traditional transplantation modifies the commitment to saving lives. Problems such as those associated with immunosuppression might seem to provide a compelling reason to oppose extension of transplantation to non-lifesaving situations. A closer examination, however, shows that immunosuppression does not present an intractable objection. For some organ transplants, such as the uterus, use of immunosuppression could be limited to the childbearing years. Complexities associated with assessment of quality of life are discussed using the example of hand transplantation. Assessment of success and functionality in a hand transplant is more complicated than it might appear at first. These complications suggest that monitoring and assessment should be a part of any extension of organ transplantation. Informed consent provides a limited, but important, component in justifying extended transplantation. Such justification, however, does not rest on patient autonomy, but on the reasonable prospect of benefit. Transplant programs considering an extension of traditional transplantation should develop formal protocols that include assessment of costs, benefits, quality of life, and the adequacy of informed consent.

Entities:  

Mesh:

Year:  2003        PMID: 12764530

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  3 in total

Review 1.  Hand transplant surgery.

Authors:  M Nassimizadeh; A K Nassimizadeh; D Power
Journal:  Ann R Coll Surg Engl       Date:  2014-11       Impact factor: 1.891

Review 2.  Until they have faces: the ethics of facial allograft transplantation.

Authors:  G J Agich; M Siemionow
Journal:  J Med Ethics       Date:  2005-12       Impact factor: 2.903

3.  Uterine transplantation and IVF for congenital or acquired uterine factor infertility: A systematic review of safety and efficacy outcomes in the first 52 recipients.

Authors:  Jessica Daolio; Stefano Palomba; Simone Paganelli; Angela Falbo; Lorenzo Aguzzoli
Journal:  PLoS One       Date:  2020-04-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.